Segulah IV L.P. divests CCS Healthcare

1 March, 2019

On March 1, 2019, Segulah IV L.P. and minority shareholders signed an agreement to divest 100% of CCS Healthcare Holding AB to KiiltoClean Group. KiiltoClean Group is a part of Kiilto, a family-owned Finnish company that develops, manufactures and markets chemical industry solutions and operates in four business areas: construction, industrial bonding and hygiene solutions, professional cleanliness and hygiene and consumer products. The transaction was simultaneously carried through.

CCS Healthcare provides hygiene and safety products to the professional business-to-business markets and holds the leading position within hand hygiene and surface disinfection products in the Nordic region. Additionally, the Company holds a strong position within portable eyewash products in Denmark and Germany.

CCS Healthcare was acquired by Segulah IV in May 2011. During Segulah IV’s ownership, CCS Healthcare has completed four add-on acquisitions, mainly within the hygiene product segment. In March 2016, CCS Healthcare divested its pharma portfolio and Clinomyn brand to Trimb Healthcare. The Consumer Skincare business unit was divested through two separate transactions in January 2019. The skincare brand portfolio was acquired by Trimb Healthcare and the factory and contract manufacturing activities in Sweden were acquired by Svenska Krämfabriken. Pro forma for the Consumer Skincare divestment, CCS Healthcare generated revenues of ca. MSEK 440 in 2018.

“CCS Healthcare has in recent years significantly transformed its operations and showed good profitable growth. Following the successful divestment of the Consumer Skincare business unit, the industrial merit of combining CCS Healthcare with Kiilto is evident, creating a Nordic powerhouse positioned for future growth”, says Dario Aganovic, CEO of CCS Healthcare.

”We are very pleased with how CCS Healthcare has performed over the past years under the leadership of the current management team. We are convinced that Kiilto as a new owner will be able to further develop CCS Healthcare’s strong position across key Nordic and European markets”, says Sebastian Ehrnrooth, Chairman of Segulah Advisor AB.



For further information please contact:

Dario Aganovic, CEO, CCS Healthcare, +46 72 555 11 01

Sebastian Ehrnrooth, Chairman, Segulah Advisor AB, +46 73 360 42 05

Johan Möllerström, Director, Segulah Advisor AB, +46 72 543 79 11

  • Download PDF
  • News Archive